PressOctober 23, 2024 Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia
PressOctober 22, 2024 Mindbio Completes Final Post Treatment Milestone in Phase 2A Microdosing Depression Clinical Trial
PressOctober 18, 2024 Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
PressOctober 17, 2024 Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
PressOctober 16, 2024 Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
PressOctober 15, 2024 Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
PressOctober 10, 2024 Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
PressOctober 10, 2024 Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
PressOctober 10, 2024 Clearmind Medicine : FDA approval for the IND submission to conduct its trial already secured Form 6K
PressOctober 9, 2024 PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
PressOctober 9, 2024 MindBio Develops Long Term Shelf-Stable Microdosing Formulation and is Progressing in Multiple Phase 2B Clinical Trials
PressOctober 7, 2024 Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
PressOctober 7, 2024 Filament Health Announces Issuance of Common Shares to Negev Capital Investments Limited Pursuant to Advisory Agreement
PressOctober 4, 2024 Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
PressOctober 4, 2024 Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
PressOctober 2, 2024 Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™